# Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Canonical URL: https://biopharmsignal.com/news/SRPT/sarepta-announces-that-screening-and-enrollment-are-underway-in-endeavor-cohort-8-to-evaluate-enhanced-immunosuppression-regimen-as-part-of-elevidys-gene-therapy-for-non-ambulant-individuals-with-duchenne
Ticker: SRPT
Company: Sarepta Therapeutics
Source: Sarepta Therapeutics
Published: 2026-03-16 12:33 EST
Original Source URL: https://investorrelations.sarepta.com
## Summary

- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver failure (ALF) associated with AAV gene therapy in

## Article Body
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver failure (ALF) associated with AAV gene therapy in
## Recent Company News
- 2026-06-01 20:30 EST — [Sarepta Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Sarepta Therapeutics
- 2026-05-13 20:30 EST — [Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference) — Source: Sarepta Therapeutics
- 2026-05-06 20:05 EST — [Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2026-financial-results-and-recent-corporate-developments) — Source: Sarepta Therapeutics
- 2026-04-22 12:30 EST — [Sarepta Therapeutics to Announce First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results) — Source: Sarepta Therapeutics
- 2026-03-31 20:05 EST — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sarepta Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)